Financials data is unavailable for this security.
View more
Year on year Medicamen Biotech Ltd 's net income fell -26.36% from 148.44m to 109.31m despite revenues that grew 27.29% from 1.41bn to 1.79bn. An increase in the selling, general and administrative costs as a percentage of sales from 15.49% to 18.03% was a component in the falling net income despite rising revenues.
Gross margin | 46.89% |
---|---|
Net profit margin | 3.52% |
Operating margin | 6.41% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Medicamen Biotech Ltd fell by 59.93m. Cash Flow from Financing totalled 63.14m or 3.52% of revenues. In addition the company used 67.44m for operations while cash used for investing totalled 55.63m.
Cash flow per share | 12.01 |
---|---|
Price/Cash flow per share | 41.83 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -27.56%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
Div yield(5 year avg) | 0.11% |
---|---|
Div growth rate (5 year) | 0.00% |
Payout ratio (TTM) | 15.69% |
EPS growth(5 years) | -3.43 |
---|---|
EPS (TTM) vs TTM 1 year ago | -33.64 |
More ▼